戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 self-reported, doctor-diagnosed arthritis or rheumatism.
2 lege of Rheumatology-European League against Rheumatism (ACR-EULAR) major clinical response, and the
3 tology (formerly the European League Against Rheumatism)/American College of Rheumatology classificat
4 study was to develop European League Against Rheumatism/American College of Rheumatology classificati
5 on criteria from the European League Against Rheumatism and American College of Rheumatology, novel d
6 edicine (Incarvillea sinensis) used to treat rheumatism and pain in humans.
7 meetings of both the European League Against Rheumatism and the American College of Rheumatology was
8 ve initiative of the European League Against Rheumatism and the American College of Rheumatology.
9 ously undisclosed or undiagnosed palindromic rheumatism and was deemed unlikely to be related to vacc
10 tis subjects participating in the Arthritis, Rheumatism, and Aging Medical Information System (ARAMIS
11 ished RA and 38 controls, and the Arthritis, Rheumatism, and Aging Medical Information System cohort,
12 loped a Markov model based on the Arthritis, Rheumatism, and Aging Medical Information System Post-Ma
13 ast 6 months apart from 6 ARAMIS (Arthritis, Rheumatism, and Aging Medical Information System) databa
14 l patients were selected from the Arthritis, Rheumatism, and Aging Medical Information Systems databa
15 y used to treat infections, kidney diseases, rheumatism, and diabetes.
16 of Rheumatology, the European League Against Rheumatism, and the Outcome Measures in Rheumatology Ini
17 eview, we explore the concept of palindromic rheumatism as part of the RA continuum and propose an up
18 lege of Rheumatology (formerly, the American Rheumatism Association) 1987 criteria or all cases of se
19 lege of Rheumatology (formerly, the American Rheumatism Association) 1987 revised criteria were reque
20 penhagen University Hospital; and The Danish Rheumatism Association.
21 lege of Rheumatology [formerly, the American Rheumatism Association] 1977 criteria) among Rochester,
22 lege of Rheumatology [formerly, the American Rheumatism Association] 1987 criteria) between 1955 and
23 lege of Rheumatology [formerly, the American Rheumatism Association]) first developed between 1955 an
24  of Rheumatology and European League Against Rheumatism classification criteria for rheumatoid arthri
25 lege of Rheumatology/European League Against Rheumatism classification criteria were included.
26 CR) and the 2010 ACR/European League Against Rheumatism classification criteria.
27  of Rheumatology/the European League Against Rheumatism clinical classification criteria for SSc.
28  early RA who took part in the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study.
29 in 184 RA families from the UK Arthritis and Rheumatism Council Repository, each containing at least
30 ant for RA, recruited from the Arthritis and Rheumatism Council Twin Study.
31 ood responses on the European League Against Rheumatism criteria (P < 0.0001) reflected the ACR crite
32 lege of Rheumatology/European League Against Rheumatism criteria and were matched 1:2 to controls pat
33 ied according to the European League Against Rheumatism criteria for improvement in RA.
34 therapy according to European League Against Rheumatism criteria, with a sensitivity of 88.9% and a s
35 ts selected from the European League Against Rheumatism database of patients with rheumatic disorders
36 ts selected from the European League Against Rheumatism database, which comprises patients with rheum
37 SLE patients met the European League Against Rheumatism (EULAR) and the American College of Rheumatol
38 f Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for rheumatoi
39 f Rheumatology (ACR)-European League Against Rheumatism (EULAR) classification criteria for rheumatoi
40 s measured using the European League Against Rheumatism (EULAR) criteria, have persistent circulating
41 e measured using the European League Against Rheumatism (EULAR) criteria.
42 ive RA, defined as a European League Against Rheumatism (EULAR) Disease Activity Score in 28 joints (
43 nse according to the European League Against Rheumatism (EULAR) response criteria (n = 505) with RA p
44 n 28 joints, and the European League against Rheumatism (EULAR) response criteria at 24 weeks.
45 s assessed using the European League Against Rheumatism (EULAR) response criteria.
46                      European League Against Rheumatism (EULAR) response rates at 6 months were compa
47 ric response and the European League Against Rheumatism (EULAR) response were also determined for the
48 n 28 joints (DAS28), European League Against Rheumatism (EULAR) response, and American College of Rhe
49  28 joint counts and European League Against Rheumatism (EULAR) response.
50 nse according to the European League Against Rheumatism (EULAR) scale at week 24.
51 tology (ACR) and the European League against Rheumatism (EULAR) were assessed at week 24 (primary ana
52 Recommendations from European League Against Rheumatism (EULAR), EULAR Scleroderma Trials and Researc
53 h PAN fulfilling the European League Against Rheumatism (EULAR)/Paediatric Rheumatology European Soci
54 ry endpoint was the "European League Against Rheumatism" (EULAR) responder rate at week 1.
55  pattern of inflammation seen in palindromic rheumatism has interesting parallels with that seen in o
56 Rheumatology and the European League Against Rheumatism have developed new classification criteria fo
57 ervation that most patients with palindromic rheumatism have RA-related autoantibodies and that many
58 ccording to the International League Against Rheumatism (ILAR) classification, seven mutually exclusi
59                                  Palindromic rheumatism is a distinctive syndrome that has a long-rec
60                                  Palindromic rheumatism is characterized by intermittent flares of pa
61 eventually develop RA has led to palindromic rheumatism often being viewed as a relapsing-remitting v
62       To discuss the European League Against Rheumatism recommendations in the management of primary
63 as defined using the European League Against Rheumatism response criteria.
64 al analyses of DAS28/European League Against Rheumatism response, and change from baseline in each pa
65 rtion meeting EULAR (European League Against Rheumatism) response criteria.
66 umatology; formerly, European League Against Rheumatism) response to treatment at month 12 assessed t
67 sponses (DAS28<2.6), European League Against Rheumatism responses, and systemic markers such as the C
68 isease (ie, Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity Index [Cl
69 from baseline in the European League Against Rheumatism Sjogren's Syndrome Disease Activity Index at
70 from baseline in the European League Against Rheumatism Sjogren's Syndrome Patient Reported Index at
71 inical and imaging phenotypes of palindromic rheumatism suggest important distinctions from RA and im
72 the core measures of European League Against Rheumatism; the Hospital Anxiety and Depression Scale; d
73 culitis have led the European League Against Rheumatism to publish recommendations in the diagnosis,